A cancer treatment breakthrough

Painless, no side effects, improved patient outcomes

The TheraBionic P1 device is FDA approved for treatment of hepatocellular carcinoma, the most common form of liver cancer. Patients 18 and older with advanced HCC who have failed first and second line therapies are eligible for treatment with the TheraBionic P1 device.

Patients using the TheraBionic P1 device did not report the debilitating side effects associated with other cancer-fighting therapies. In fact, in multiple clinical trials, patients have reported no side effects with the TheraBionic P1 device.

For patients with advanced HCC, given the TheraBionic P1’s lack of liver toxicity, it is not expected that use of the TheraBionic P1 device will further impair the patient’s liver function. Additionally, patients are less likely to experience hospital readmissions due to complications that can arise with cancer treatment drugs.

Patients with advanced HCC who have failed first and second line therapies generally have a life expectancy of about four months. With the TheraBionic P1 therapy, life expectancy was increased to about nine months among patients who had received two separate forms of systemic therapy. Overall, in studies of patients with liver cancer, survival rates increased by 34 percent using the TheraBionic P1 therapy.

Our Science

TheraBionic Mechanism of Action

TheraBionic Clinical Trial Research and Device Treatment focuses on:

  • Treatment efficacy

  • Minimizing adverse events

  • Symptomatic benefit

  • Convenience of treatment

TheraBionic Mechanism of Action

  • Development of novel electromagnetic field emitting devices and methods for pulse pressure measurement led to the identification of changes in pulse pressure upon exposure to specific frequencies*

  • Discovery of tumor-specific amplitude-modulated (AM) radiofrequency (RF) electromagnetic fields (EMF) through patient-based research

  • Pulse pressure changes occur at similar frequencies for patients with the same type of cancer, irrespective of gender, age, and ethnic status

  • Frequencies eliciting the best pulse pressure responses, defined by the magnitude of increased amplitude and/or the number of heartbeats with increased amplitude, are selected as tumor-specific frequencies

  • Control individuals without a diagnosis of cancer do not exhibit changes in pulse pressure upon exposure to frequencies identified in patients with a diagnosis of cancer

  • Identification of the intracellular pathways modulated by AM RF EMF

  • Identification of the receptor for tumor-specific frequencies on cancer cells

* Response to radio frequencies is indicated by changes in the patient’s pulse pressure.

Physician Contact Form